Universal API Implementation Guide
1.1.20 - ci-build

Universal API Implementation Guide - Local Development build (v1.1.20) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Release 2026 Feb 06

ANNOUNCEMENTS

IMPORTANT: UAPI - GPF Prescriber Form Changes

  • Updated GPF Prescriber Form (V6) will go into effect 1/1/2026
  • Current GPF Prescriber Form (V5) will be valid until 3/31/2026
  • Existing GPF questionnaires will remain as is, unless they are listed in the Removed table below. You should continue to include existing questionnaires in the FHIR bundle if they were required on the old form.
  • The Patient Foundation is now requiring that insurance cards be sent to them. Since we do not accept files on our APIs, you have the following options to send the insurance cards (front/back) to Genentech:
    • Fax to the Patient Foundation (833) 999-4363
    • HCPs who are registered for MPS (My Patient Solution portal) can do the following:
      • HCPs can send a Secure Email via MPS and attach patient insurance card
      • Effective 3/9/2026, HCPs can upload copies of their insurance cards in MPS
    • Your own internal fax Solution
  • All questionnaires updated to reflect the GPF changes and can be accessed via postman:


REMOVED

Available in Test Environment Product LinkId Text Prescriber Form Version valid until: Comments
Yes All Products "linkId": "ins-denial-reason" "Denial reason (or attach copy of denial letter):" 3/31/2026 (v5) Previously included in Step 1
Yes All Products "linkId": "ins-denial-date" "For insurance denials, provide denial date:" 3/31/2026 (v5) Previously included in Step 1


ADDITIONS

Available in Test Environment Product linkId Text Section on GPF form GPF Prescriber Form Version Comments
Yes All Products "linkId": "sot-hcp-affiliate" "Is the third-party site of treatment affiliated with the same health system as the prescriber?" Step 4 1/1/2026 (v6)  
Yes All Products "linkId": "has-insurance" "Does the patient have any health insurance?" Step 2 1/1/2026 (v6)  
Yes All Products "linkId": "denied-coverage" "If insured, has the patient's insurance denied coverage for this medication?" Step 2 1/1/2026 (v6) include this linkId in FHIR bundle if patient is insured


EXCLUDED - Questionnaires to be excluded from FHIR bundle

The following GPF questions will not be required to be answered as Genentech will automatically populate on your behalf:

Product Text Section on GPF form Comments
All Products "Are copies of all insurance card(s) attached?" Step 2 We will automatically populate "NO" on GPF form
All Products "Are insurance denial letter(s) and other documentation attached?" Step 2 We will automatically answer "NO" on GPF form


OTHER GPF Update Information

  • Under Step 4, if "Shipment to" = Prescriber, Practice or Site of Treatment, then the Treatment Site info should be provided.
  • "Shipment to" is dependent on product. Options for each product can be found in product tables in the Implementation Guide > Business Rules > AS-GPF Enrollment - Products Specifics or the in questionnaire for each product.
  • If Shipment to = "Site of Treatment" (linkID: 'Ship-to"), then it's assumed that linkID: "pos" = Hospital Outpatient or Infusion Center
  • If Shipment to = "Site of Treatment", then the following should be included in the FHIR bundle


(1) Include linkId: "site-of-treatment-2" questionnaire in bundle.

    {
            "linkId" : "site-of-treatment-2",
            "text" : "Third-party Site of Treatment",
            "answer" : [
              {
                "valueReference" : {
                  "reference" : "urn:uuid:45cf0b29-8c1d-4882-91e1-00bc28c06a52", <----- The uuid of the Organization resource for the SOT
                  "type" : "Organization"
                }
              }
            ]
          },



(2) Include an Organization resource for the Site of Treatment where Organization.type.coding.code = other (partial sample below).
Example of SOT organization resource

{
  "resourceType" : "Organization",
  "id" : "45cf0b29-8c1d-4882-91e1-00bc28c06a52",
  "meta" : {
    "profile" : [
      "🔗", "https://fhir.developer.gene.com/StructureDefinition/uapi-organization"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : ""
  },
  "identifier" : [
    {
      "use" : "usual",
      "system" : "http://SOT.com",
      "value" : "SOT-001",
      "assigner" : {
        "display" : "Florida Hospital Orlando Infusion Center"
      }
    }
  ],
  "type" : [
    {
      "coding" : [
        {
          "system" : "http://terminology.hl7.org/CodeSystem/organization-type",
          "code" : "other",
          "display" : "Site of Treatment"
        }
      ],
      "text" : "Site of Treatment"
    }
  ],
  "name" : "FLORIDA HOSPITAL ORLANDO INFUSION CNTR"}



COPAY - Lunsumio and Lunsumio Velo

Questionnaires for Copay enrollments can be accessed by requesting Lunsumio Velo Copay questionnaire definitions from the Genentech FHIR Server.

URL to Copay Questionnaire endpoint (test): https://test-us-e1.apis.roche.com/pharma-cmg-copay-exp-test/v1/questionnaire?name=Copay Lunsumio Velo
URL to Copay Questionnaire endpoint (stage): https://stage-us-e1.apis.roche.com/pharma-cmg-copay-exp-stage/v1/questionnaire?name=Copay Lunsumio Velo
URL to Copay Questionnaire endpoint (prod): https://prod-us-e1.apis.roche.com/pharma-cmg-copay-exp-prod/v1/questionnaire?name=Copay Lunsumio Velo

Lunsumio Velo - BrandIds

Refer to brandIds table on Copay Value Set page

Lunsumio Velo - FDA Indications (ICD10)

FDA approved indications (ICD10 codes) can be found on the Access Solutions website for Lunsumio Velo



Lunsumio & Lunsumio Velo Questionnaire Updates

Type Release to Production Available in QA (test) environment? Product(s) impacted linkId impacted (if applicable) OLD New Comment
Addition 2/6/2026 Yes Lunsumio

Lunsumio Velo
lunsumio-form-of-lunsumio

lunsumio-velo-form-of-lunsumio
- Text: "Which form of LUNSUMIO are you taking?"

"valueString": "Intravenous infusion (IV) for LUNSUMIO"

"valueString": "Subcutaneous (SC) injection for LUNSUMIO VELO"

same for both Lunsumio & Lunsumio Velo
Update 2/6/2026 Yes Lunsumio lunsumio-fda-approved-indications Text: Is the patient using LUNSUMIO® (mosunetuzumab-axgb) for the following FDA-approved indication?

LUNSUMIO is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if LUNSUMIO is safe and effective in children. The conditional approval of LUNSUMIO is based on response rate. There are ongoing studies to establish how well the drug works.
Is the patient using LUNSUMIO® (mosunetuzumab-axgb) or LUNSUMIO VELO™ (mosunetuzumab-axgb) for the following FDA-approved indication?


Adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer.

It is not known if LUNSUMIO or LUNSUMIO VELO is safe and effective in children.

The conditional approval of LUNSUMIO and LUNSUMIO VELO is based on response rate. There are ongoing studies to establish how well the drug works.
 
Add 2/6/2026 Yes Lunsumio Velo lunsumio-velo-fda-approved-indications - Is the patient using LUNSUMIO® (mosunetuzumab-axgb) or LUNSUMIO VELO™ (mosunetuzumab-axgb) for the following FDA-approved indication?


Adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer.

It is not known if LUNSUMIO or LUNSUMIO VELO is safe and effective in children.

The conditional approval of LUNSUMIO and LUNSUMIO VELO is based on response rate. There are ongoing studies to establish how well the drug works.